Literature DB >> 11122867

New developments in autologous tumor cell vaccination therapy for renal cell carcinoma.

A J van den Eertwegh 1, H M Pinedo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11122867     DOI： 10.1007/s11912-000-0053-5

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  23 in total

Review 1.  T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal.

Authors:  P Kaliński; C M Hilkens; E A Wierenga; M L Kapsenberg
Journal:  Immunol Today       Date:  1999-12

2.  CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help.

Authors:  R R French; H T Chan; A L Tutt; M J Glennie
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

Review 3.  Cancer vaccines: reborn or just recycled?

Authors:  D Berd
Journal:  Semin Oncol       Date:  1998-12       Impact factor: 4.929

Review 4.  Renal-cell carcinoma.

Authors:  R J Motzer; N H Bander; D M Nanus
Journal:  N Engl J Med       Date:  1996-09-19       Impact factor: 91.245

5.  Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283.

Authors:  J E Harris; L Ryan; H C Hoover; R K Stuart; M M Oken; A B Benson; E Mansour; D G Haller; J Manola; M G Hanna
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

6.  Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.

Authors:  E D Kwon; B A Foster; A A Hurwitz; C Madias; J P Allison; N M Greenberg; M B Burg
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

7.  Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines.

Authors:  M L Disis; H Bernhard; F M Shiota; S L Hand; J R Gralow; E S Huseby; S Gillis; M A Cheever
Journal:  Blood       Date:  1996-07-01       Impact factor: 22.113

8.  A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma.

Authors:  R G Fenton; R G Steis; K Madara; A H Zea; A C Ochoa; J E Janik; J W Smith; B L Gause; W H Sharfman; W J Urba; M G Hanna; R L DeJager; M X Coyne; R D Crouch; P Gray; J Beveridge; S P Creekmore; J Holmlund; B D Curti; M Sznol; D L Longo
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1996-09

9.  Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis.

Authors:  D T Sleijfer; R A Janssen; J Buter; E G de Vries; P H Willemse; N H Mulder
Journal:  J Clin Oncol       Date:  1992-07       Impact factor: 44.544

Review 10.  Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer.

Authors:  K K Bass; M J Mastrangelo
Journal:  Cancer Immunol Immunother       Date:  1998-09       Impact factor: 6.968
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.